Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2022-03-30 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
2021年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for the year 2021 of 东北制药集团股份有限公司 (Northeast Pharmaceutical Group Co., Ltd.). It is issued by 致同会计师事务所 (Grant Thornton), a registered accounting firm, and includes detailed audit opinions, basis for audit opinions, key audit matters, and extensive financial statements including balance sheets, profit and loss statements, cash flow statements, and notes. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content is consistent with a standalone audit report rather than a full annual report or other filing types. Therefore, the appropriate classification is Audit Report / Information (AR).
2022-03-30 Chinese
年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of Dongbei Pharmaceutical Group Co., Ltd. It includes information about the meeting date, voting procedures, agenda items, and proxy voting instructions. The document does not contain the actual annual report or financial statements but rather the announcement and procedural details for the AGM. The document length is 4400 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2022-03-30 Chinese
关于公司为全资子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a listed company (东北制药集团股份有限公司) regarding the provision of guarantees for its wholly-owned subsidiaries. It includes detailed information about the guarantee amounts, the subsidiaries involved, their financial data, and the board's opinions on the guarantees. The document is structured as a formal announcement with no indication that it is a full financial report or audit report. It does not contain comprehensive financial statements or management discussion and analysis typical of annual or interim reports. Instead, it focuses on a specific corporate action related to financing and guarantees. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes such as guarantees provided to subsidiaries.
2022-03-30 Chinese
关于拟续聘公司2022年度审计机构的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of the company's audit firm for the 2022 fiscal year. It details the qualifications, independence, and past performance of the audit firm, as well as the approval process by the board and audit committee. It does not contain actual financial statements or audit results but rather discusses the appointment process and related information. The document length is 4169 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR) because it relates specifically to audit matters but is not the audit report itself. However, since it is an announcement about the audit firm appointment and not the audit report or results, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about audit firm appointment, which does not fit other categories better.
2022-03-30 Chinese
2021年度独立董事述职报告（商有光）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2021 from a specific independent director of the company. It details the director's attendance at meetings, independent opinions on various board matters, committee duties, investigations into company management, investor protection activities, and other related work. The content is a narrative report on the director's activities and opinions rather than a financial report, audit, or regulatory filing. It is not an announcement or a brief notice but a detailed report on the independent director's duties and observations for the year. This type of document fits best under Board/Management Information (MANG), as it relates to board members' activities and governance roles rather than financial results or regulatory compliance filings.
2022-03-30 Chinese
2021年度独立董事述职报告（姚辉）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2021 by an independent director of Northeast Pharmaceutical Group Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, opinions on various board matters, committee duties, and efforts to protect investor rights. The content focuses on governance, oversight, and compliance with laws and regulations, rather than financial results or audit opinions. It is a detailed report on board/management activities and independent director duties rather than a financial report or announcement. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 3602 characters, which is relatively short but contains substantive content about board activities, not just an announcement or certification, so it is not RPA or RNS.
2022-03-30 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.